Vosevi (sofosbuvir, velpatasvir and voxilaprevir)
What is Vosevi?
On July 18, 2017 the U.S. Food and Drug Administration approved the prescription medication Vosevi™ (sofosbuvir, velpatasvir and voxilaprevir). Vosevi is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, velpatasvir, an HCV NS5A inhibitor, and voxilaprevir, an HCV NS3/4A protease inhibitor, and is indicated for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis who have genotype 1-6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor or genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor
The active ingredients per tablet of Vosevi are 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg of voxilaprevir.
Last Updated: October 2017
"FDA approves Vosevi for Hepatitis C" FDA.gov. U.S. Food & Drug Administration. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm567467.htm. Retrieved October 6, 2017.
"Highlights of Prescribing Information." Gilead.com. Gilead Sciences Inc., http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/vosevi/vosevi_pi.pdf. Retrieved October 6, 2017.
"Vosevi is FDA approved." Vosevi.com. Gilead Sciences Inc., http://www.vosevi.com/. Retrieved October 6, 2017.